IDH1 and astrocytoma (excluding glioblastoma): In patients with IDH-mutant grade 2 astrocytoma, evidence for an overall survival benefit from radiotherapy (RT) plus chemotherapy (PCV or temozolomide) over RT alone stems from multiple trials.